Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $85.96 +1.10 (+1.30%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$85.24 -0.71 (-0.83%) As of 05/30/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DexCom Stock (NASDAQ:DXCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DexCom alerts:Sign Up Key Stats Today's Range$84.85▼$86.8050-Day Range$59.83▼$87.3452-Week Range$57.52▼$120.48Volume4.26 million shsAverage Volume4.36 million shsMarket Capitalization$33.71 billionP/E Ratio60.11Dividend YieldN/APrice Target$98.32Consensus RatingModerate Buy Company OverviewDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More… DexCom Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 96% of companies evaluated by MarketBeat, and ranked 46th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth21.18% Earnings GrowthEarnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 60.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.27.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 60.11, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 15.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.90% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 1.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted2.90% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 1.14%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.15 News SentimentDexCom has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for DexCom this week, compared to 25 articles on an average week.Search InterestOnly 10 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,103,505.00 in company stock.Percentage Held by InsidersOnly 0.32% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesDexCom Stock: Earnings Beat and New Market Access Drive Bull CaseDexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market.May 8, 2025 | marketbeat.comDexCom (NASDAQ:DXCM) Coverage Initiated at The Goldman Sachs GroupJune 1 at 2:20 AM | americanbankingnews.comHow I make 💰 trading from 135 countries I’ve traveled to 135 countries… In a new time zone almost every week… (Often 8… 12… 16 hours AHEAD of the United States) And yet I’ve made $7.9 million career profits… trading in the US markets?June 1, 2025 | Timothy Sykes (Ad)Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy RecommendationMay 31 at 4:37 AM | msn.comGoldman Sachs Initiates Coverage of DexCom (DXCM) With Buy RatingMay 30 at 11:35 PM | msn.comDexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock NewsMay 29 at 10:37 PM | gurufocus.comPrediction: These 2 Stocks Will Beat the Market in the Next DecadeMay 27, 2025 | fool.com2 Momentum Stocks with Impressive Fundamentals and 1 to AvoidMay 26, 2025 | finance.yahoo.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $77.77 at the beginning of the year. Since then, DXCM stock has increased by 10.5% and is now trading at $85.96. View the best growth stocks for 2025 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Thursday, May, 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.01. DexCom's revenue was up 12.5% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were payable to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others. Who are DexCom's major shareholders? Top institutional investors of DexCom include Vanguard Group Inc. (12.10%), Baillie Gifford & Co. (3.62%), Jennison Associates LLC (2.68%) and UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (2.58%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan and Bridgette P Heller. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/01/2025Today6/01/2025Next Earnings (Estimated)7/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees7,600Year Founded1999Price Target and Rating Average Stock Price Target$98.32 High Stock Price Target$120.00 Low Stock Price Target$82.00 Potential Upside/Downside+14.4%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$1.34 Trailing P/E Ratio60.11 Forward P/E Ratio42.34 P/E Growth2.3Net Income$576.20 million Net Margins14.29% Pretax Margin17.58% Return on Equity30.14% Return on Assets10.11% Debt Debt-to-Equity Ratio0.59 Current Ratio1.47 Quick Ratio1.28 Sales & Book Value Annual Sales$4.15 billion Price / Sales8.13 Cash Flow$2.16 per share Price / Cash Flow39.75 Book Value$5.38 per share Price / Book15.98Miscellaneous Outstanding Shares392,107,000Free Float389,600,000Market Cap$33.71 billion OptionableOptionable Beta1.43 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:DXCM) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.